Related Insights

Blog

Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development

Jun 22, 2021

Blog

CAR-T product development: an assessment of FDA’s final guidance for industry

Feb 27, 2024

Video

Overcoming asset transfer challenges during a merger and acquisition (M&A)

Oct 20, 2021

Article

EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022

Blog

Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Podcast

RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022

Blog

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022

Article

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022

Video

On-demand webinar: An expert guide to EU-CTR

Mar 10, 2022

Blog

Six steps to maximize inclusivity within medical communications | Part 1: Race and Ethnicity

Mar 3, 2022

Article

New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022